secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001549595-25-000094
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL
--------------------------------------------------------------------------------

- Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.
- Net loss $43.5M ($0.52/sh) vs $44.5M ($0.71/sh) prior year; cash $485.8M.
- Sanofi extended STAT6 license for $15M payment; total $127M received; up to $465M in milestones remain.
- Bexobrutideg Phase 1 data: 80.9% ORR in r/r CLL including a complete response; favorable safety (no AFib, fungal infections).
- FDA cleared IND for IRAK4 degrader GS-6791/NX-0479; pivotal CLL trial for bexobrutideg expects to start H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/0001549595-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/nrix-20250709.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer